Povetacicept FDA Approval Decision Due Nov 30: What Vertex’s IgA Nephropathy Drug Showed
The FDA is due to decide on Vertex's povetacicept for IgA nephropathy by 30 November 2026, after a 49.8% proteinuria cut versus placebo in the RAINIER trial.
The FDA is due to decide on Vertex's povetacicept for IgA nephropathy by 30 November 2026, after a 49.8% proteinuria cut versus placebo in the RAINIER trial.